JP Morgan Chase’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $21.5M | Buy |
+111,000
| New | +$21.4M | ﹤0.01% | 2011 |
|
|
2025
Q2 | – | Sell |
-18,950
| Closed | -$2.79M | – | 7068 |
|
|
2025
Q1 | $2.79M | Sell |
18,950
-10,800
| -36% | -$1.56M | ﹤0.01% | 3616 |
|
|
2024
Q4 | $3.9M | Sell |
29,750
-250
| -0.8% | -$35K | ﹤0.01% | 3589 |
|
|
2024
Q3 | $4.67M | Sell |
30,000
-11,100
| -27% | -$1.79M | ﹤0.01% | 3265 |
|
|
2024
Q2 | $6.41M | Buy |
41,100
+11,100
| +37% | +$1.67M | ﹤0.01% | 2835 |
|
|
2024
Q1 | $4.07M | Hold |
30,000
| – | – | ﹤0.01% | 3273 |
|
|
2023
Q4 | $4.04M | Sell |
30,000
-127,950
| -81% | -$16.6M | ﹤0.01% | 3275 |
|
|
2023
Q3 | $21.4M | Buy |
+157,950
| New | +$21.6M | ﹤0.01% | 1625 |
|
|
2023
Q2 | – | Sell |
-4,400
| Closed | -$611K | – | 6910 |
|
|
2023
Q1 | $611K | Sell |
4,400
-3,600
| -45% | -$484K | ﹤0.01% | 4358 |
|
|
2022
Q4 | $1.08M | Buy |
+8,000
| New | +$1M | ﹤0.01% | 3985 |
|
|
2021
Q1 | – | Sell |
-32,500
| Closed | -$3.25M | – | 6057 |
|
|
2020
Q4 | $3.25M | Hold |
32,500
| – | – | ﹤0.01% | 3139 |
|
|
2020
Q3 | $3.58M | Sell |
32,500
-17,550
| -35% | -$1.95M | ﹤0.01% | 2826 |
|
|
2020
Q2 | $5.29M | Buy |
50,050
+25,050
| +100% | +$2.59M | ﹤0.01% | 2410 |
|
|
2020
Q1 | $2.23M | Hold |
25,000
| – | – | ﹤0.01% | 2881 |
|
|
2019
Q4 | $2.49M | Hold |
25,000
| – | – | ﹤0.01% | 3217 |
|
|
2019
Q3 | $2.23M | Sell |
25,000
-52,350
| -68% | -$4.54M | ﹤0.01% | 3349 |
|
|
2019
Q2 | $6.34M | Buy |
77,350
+52,350
| +209% | +$4.1M | ﹤0.01% | 2453 |
|
|
2019
Q1 | $2.02M | Hold |
25,000
| – | – | ﹤0.01% | 3316 |
|
|
2018
Q4 | $1.9M | Hold |
25,000
| – | – | ﹤0.01% | 3317 |
|
|
2018
Q3 | $1.98M | Buy |
+25,000
| New | +$1.89M | ﹤0.01% | 3475 |
|
|
2017
Q3 | – | Sell |
-50,000
| Closed | -$3.41M | – | 4959 |
|
|
2017
Q2 | $3.41M | Buy |
+50,000
| New | +$3.27M | ﹤0.01% | 2729 |
|
|
2016
Q1 | – | Sell |
-46,050
| Closed | -$3.13M | – | 4652 |
|
|
2015
Q4 | $3.13M | Sell |
46,050
-80,000
| -63% | -$5.25M | ﹤0.01% | 2504 |
|
|
2015
Q3 | $8.02M | Buy |
+126,050
| New | +$8.29M | ﹤0.01% | 1925 |
|
|
2015
Q2 | – | Sell |
-87,500
| Closed | -$5.99M | – | 4012 |
|
|
2015
Q1 | $5.99M | Sell |
87,500
-1,762,500
| -95% | -$122M | ﹤0.01% | 2222 |
|
|
2014
Q4 | $130M | Buy |
+1,850,000
| New | +$132M | 0.03% | 537 |
|
Other funds holding AZN
IA
VCM
VAM
JP Morgan Chase's AZN Position: Q1 2026 in Review
JP Morgan Chase increased its AstraZeneca (AZN) stake by 892% in Q1 2026, buying an estimated $3.22B and bringing the position to 18,590,922 shares worth $3.6B. The position accounts for 0.23% of the portfolio, ranked #95.
JP Morgan Chase first reported a position in AZN in Q2 2013 and has held it in 52 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- JP Morgan Chase held 18,590,922 shares of AstraZeneca worth $3.6B as of Q1 2026.
- JP Morgan Chase bought 16,717,429 AstraZeneca shares in Q1 2026, an estimated $3.22B.
- AstraZeneca made up 0.23% of JP Morgan Chase's portfolio in Q1 2026, its #95 holding.
- JP Morgan Chase first reported a position in AstraZeneca in Q2 2013 and has held it in 52 quarters since.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.